Acumen Pharmaceuticals announced the appointment of Dr. Amy Schacterle as Chief Regulatory Officer and Head of Quality. Dr. Schacterle will report to Jim Doherty, President and Chief Development Officer. This appointment strengthens the company's leadership in regulatory affairs.
Dr. Schacterle's role is critical for guiding sabirnetug through the complex regulatory landscape as it progresses in clinical development for Alzheimer's disease. Her expertise is expected to support the company's efforts to bring its novel therapeutic to patients.
This strategic hire indicates Acumen's focus on building a robust regulatory framework. It is a key step in preparing for potential future interactions with regulatory bodies like the U.S. Food and Drug Administration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.